Table 1.
Participants’ baseline characteristics
| Vaccine single dose (SD) at 2 × 1011 vp (n = 305) | Vaccine repeated dose (RD) at 1 × 1011 vp (n = 308) | Placebo (n = 304) | |
|---|---|---|---|
| Protocol strata | |||
| Age 18 to <65 years and not at risk, n (%) | 218 (71.5) | 219 (71.1) | 215 (70.7) |
| Age 18 to <65 years and at risk, n (%) | 29 (9.5) | 30 (9.7) | 31 (10.2) |
| Age ≥65 years, n (%) | 58 (19.0) | 59 (19.2) | 58 (19.1) |
| Age, years | |||
| Mean (SD) | 46.0 (16.63) | 47.2 (16.07) | 47.3 (15.54) |
| Gender, n (%) | |||
| Male | 197 (64.6) | 200 (64.9) | 184 (60.5) |
| Female | 108 (35.4) | 108 (35.1) | 120 (39.5) |
| Body mass index, kg/m2 | |||
| Mean (SD) | 25.3 (4.4) | 25.0 (4.4) | 25.6 (4.6) |
| Underlying diseases, n (%) | |||
| None | 267 (87.5) | 270 (87.7) | 261 (85.9) |
| Significant cardiac diseases | 12 (3.9) | 14 (4.5) | 17 (5.6) |
| Chronic lung diseases | 9 (3.0) | 8 (2.6) | 6 (2.0) |
| Severe obesity | 3 (1.0) | 3 (1.0) | 6 (2.0) |
| Diabetes (type 1, type 2) | 7 (2.3) | 6 (1.9) | 6 (2.0) |
| Liver diseases | 2 (0.7) | 3 (1.0) | 3 (1.0) |
| HIV infection | 9 (3.0) | 7 (2.3) | 6 (2.0) |
vp, viral particles.